Article

Benznidazole-Related Adverse Drug Reactions and Their Relationship With Serum Drug Concentrations in Patients With Chronic Chagas Disease.

Health Biostatistics. Centre for International Health Research (CRESIB). Roselló, 132. 08036 Barcelona. Spain
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 10/2012; 57(1). DOI: 10.1128/AAC.01401-12
Source: PubMed

ABSTRACT For treating Chagas disease (CD), currently a worldwide health problem, only benznidazole and nifurtimox have been approved to be used. In both cases, unwanted drug-related adverse events (ADRs) are frequent when theses drugs are used in adults in the chronic stage. The main objective of this study was to establish benznidazole-ADRs and its relationship with serum concentrations in patients with chronic T. cruzi infection in order to perform a more accurate dosage to minimize ADRs.Fifty-four patients were recruited during 12 months. Fifty-three (98%) of the 54 patients had at least one ADR during follow-up, and the incidence of ADRs was 2.4 episodes/patient/month. Benznidazole treatment was discontinued in 11 patients, seven among them due to severe adverse effects. The mean duration of treatment before withdrawal was 11 days.Benznidazole serum concentrations were recorded on days 15, 30, 45, and 60 of follow-up, and evaluated according clinical and epidemiological variables, and ADR severity. No relationship was found between benznidazole serum concentration and ADRs. The mean (standard deviation) trough serum benznidazole concentrations on days 15, 30, 45, and 60 were 6.4 (1.9), 6.1 (1.8), 6.2 (2.2) and 5.7 (1.7) mcg/mL, respectively. It is well known that trypanosomicidal concentration of benznidazole ranges from 3 to 6 mcg/mL, and data from our study reveals that using the established dose regime patients are overdosed.Benznidazole serum concentrations do not appear to be related to the appearance of serious ADRs. Further well-controlled studies are necessary to establish optimal dose regimen for benznidazole in adults with chronic CD.

Download full-text

Full-text

Available from: Joaquim Gascón, Oct 03, 2014
0 Followers
 · 
109 Views
 · 
22 Downloads
  • Source
    • "Adults Benznidazole Adverse events 0.59 c 0.44–0.74 a Pinazo et al. (2013), Hasslocher-Moreno et al. (2012), Pinazo et al. (2010) Withdrawals 0.23 c 0.17–0.29 a Severe adverse events Nifurtimox Adverse events 0.975 0.73–1 Jackson et al. (2010) Withdrawals 0.395 0.3–0.5 a Severe adverse events 0.074 0.056–0.093 a Children Benznidazole Adverse events 0.58 0.44–0.73 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although Spain is the European country with the highest Chagas disease burden, the country does not have a national control program of the disease. The purpose of this study is to evaluate the efficiency of several strategies for Chagas disease screening among Latin American residents living in Spain. The following screening strategies were evaluated: 1) non-screening; 2) screening of the Latin American pregnant women and their newborns; 3) screening also the relatives of the positive pregnant women; 4) screening also the relatives of the negative pregnant women. A cost-utility analysis was carried out to compare the four strategies from two perspectives, the societal and the Spanish National Health System (SNHS). A decision tree representing the clinical evolution of Chagas disease throughout patient's life was built. The strategies were compared through the incremental cost-utility ratio, using euros as cost measurement and quality-adjusted life years as utility measurement. A sensitivity analysis was performed to test the model parameters and their influence on the results. We found the "Non-screening" as the most expensive and less effective of the evaluated strategies, from both the societal and the SNHS perspectives. Among the screening evaluated strategies the most efficient was, from both perspectives, to extent the antenatal screening of the Latin American pregnant women and their newborns up to the relatives of the positive women. Several parameters influenced significantly on the sensitivity analyses, particularly the chronic treatment efficacy or the prevalence of Chagas disease. In conclusion, for the general Latin American immigrants living in Spain the most efficient would be to screen the Latin American mothers, their newborns and the close relatives of the mothers with a positive serology. However for higher prevalence immigrant population the most efficient intervention would be to extend the program to the close relatives of the negative mothers. Copyright © 2015. Published by Elsevier B.V.
    Acta tropica 04/2015; 148. DOI:10.1016/j.actatropica.2015.04.014 · 2.52 Impact Factor
  • Source
    • "Our data suggest that benznidazole, as well as nifurtimox and fexinidazole sulfone, are concentration-dependent trypanocidal drugs and therefore more efficacious at higher doses (above 100 μM, or 26 μg/mL, in the case of benznidazole). A recent study has determined the serum concentration of benznidazole in patients with chronic Chagas disease treated with 5 mg/kg/day for 60 days to range from 5 to 6.5 μg/mL on average67. This range is equivalent to 20–25 μM benznidazole, which was a suboptimal concentration (according to time-kill data in this study) against the Y strain for up to 96 h. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Advocacy for better drugs and access to treatment has boosted the interest in drug discovery and development for Chagas disease, a chronic infection caused by the genetically heterogeneous parasite, Trypanosoma cruzi. In this work new in vitro assays were used to gain a better understanding of the antitrypanosomal properties of the most advanced antichagasic lead and clinical compounds, the nitroheterocyclics benznidazole, nifurtimox and fexinidazole sulfone, the oxaborole AN4169, and four ergosterol biosynthesis inhibitors - posaconazole, ravuconazole, EPL-BS967 and EPL-BS1246. Two types of assays were developed: one for evaluation of potency and efficacy in dose-response against a panel of T. cruzi stocks representing all current discrete typing units (DTUs), and a time-kill assay. Although less potent, the nitroheterocyclics and the oxaborole showed broad efficacy against all T. cruzi tested and were rapidly trypanocidal, whilst ergosterol biosynthesis inhibitors showed variable activity that was both compound- and strain-specific, and were unable to eradicate intracellular infection even after 7 days of continuous compound exposure at most efficacious concentrations. These findings contest previous reports of variable responses to nitroderivatives among different T. cruzi strains and further challenge the introduction of ergosterol biosynthesis inhibitors as new single chemotherapeutic agents for the treatment of Chagas disease.
    Scientific Reports 04/2014; 4:4703. DOI:10.1038/srep04703 · 5.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 1,4-dihydro-4-oxoquinoline ribonucleoside, Neq135, is the first low micromolar trypanosomatidae inhibitor to show good ligand efficiency (0.28kcalmol(-1)atom(-1)) and good ligand lipophilicity efficiency (0.37kcalmol(-1)atom(-1)) when acting against Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase (TcGAPDH). This and other six ribonucleosides were synthesized using our in-house technology, and assayed against the GAPDH NAD(+) site using isothermal titration calorimetry (ITC). Compound Neq135 had acceptable in vitro cytotoxicity, inhibited TcGAPDH with a Ki(app) value of 16μM and killed the trypomastigote form of Trypanosoma cruzi Tulahuen strain with a concentration similar to that displayed by the control drug benznidazole. Neq135 is tenfold lower kinetic affinity against hGAPDH and does not kill Balb-c fibroblast nor spleen mouse cells. These results emphasize the possibility of integrating ligand- and target-based designs to uncover potent and selective TcGAPDH inhibitors that expands the opportunity for further medicinal chemistry endeavor towards NAD(+) TcGAPDH site.
    Bioorganic & medicinal chemistry letters 06/2013; 23(16). DOI:10.1016/j.bmcl.2013.06.029 · 2.33 Impact Factor
Show more